Orthocell (ASX:OCC) said its distributor unit BioHorizons Camlog, has completed the first sale and is now actively selling the company's collagen membrane device used for guided bone and tissue regeneration in dental applications Striate+, in Germany, Austria, and Switzerland, according to a Wednesday filing with the Australian bourse.
Regulatory approval for the Striate+ in Brazil is anticipated within the next three months, with additional applications currently under review, the filing said.
Price (AUD): $1.50, Change: $-0.060, Percent Change: -3.85%